Welcome to Real Talk on AI and I care with your host, Dr. Scott Morris. And I'm co host, Dr. Rehan Ahmed.
In each episode, we discuss current news, adding a little AI education, and debate innovative AI tools and topics that will change the industry. Welcome to Real Talk. This is your host today, Dr. Scott Morris.
I have a guest for all of you that I am super looking forward to. His name is Ryan Smith. He is the head of business intelligence and strategy for the last four or five years at Glacos. Ryan and I have kind of developed a friendship and talked about many things.
Ryan actually lives here in Denver with me so we get together every once in a while. And I get to forge good fortune of picking his brain because he sees things. He sees things very different. He comes from the buy side of private equity as a private equity analyst for Janus Henderson in the past.
And so he looks at what we do from a very different perspective. And I really enjoy our conversation with Ryan because he is very data driven. Give me the numbers show me where it comes from. And that's where we want to go today is picking his brain a little bit on what do we need in the I care industry for data.
So Ryan, welcome to the show. Thank you, Dr. Mars. It's a pleasure to be on here and thank you very much for for having me.
Of course, of course. So, you know, I always think about this one our conversations that you and I have. We talk about what the current I care landscape looks like. And, you know, every part of industry and every part of clinical practice is looking at maybe different data points.
But if you were to narrow it down, we'll start with us with maybe not the easiest softball in the world. I can throw you Ryan, but if you were to say what's the one data point you and your position. Look at for Glacos and go, this is the data point I wish I had better data for. It's a great question.
So I guess you know, I'd start by answering that by you know talking about a little bit of, you know, some of that kind of disparate data sets that. You know, we look at on a daily basis monthly basis on and so forth, but I think the hardest challenge, you know amongst all that is is two things one, you know, connecting the dots between. You know any and all data sources that I think that you know yourself and the audience would. What would be able to reconcile with so you know you've got medical claims data you've got prescription claims you've got diagnoses.
And then everything you know that comes with the emerging complexities of market access. So formulary policy and putting all of that together. So when we look at our products, whether they be more mature, they're emerging. I guess it you know kind of varies as to what the focal point is as to what we're looking at.
But by and large, it's really being able to connect the dots. So understanding prescriber patterns. You know treatment algorithms, whether they be uniform or not. And really I can answer that Ryan.
That's probably no. You know, I want to address what you said and you know I've had this conversation before about disparate data sources and you know you just laid that out in a different way than I think most of his clinicians think we think okay. Maybe what's our prescribing pattern or maybe what's evidence based medicine, but what you just laid out about you know you guys are looking at data from who's actually prescribing what. It does Dr.
A versus Dr. B, even though the quote unquote standard of care may be X. Dr. A and Dr.
B are doing it different based on their experience and it's probably hard to put that together and seeing you know I am always interesting. I look at pharmacy data and go. Now I wrote drug A drug B got filled or I know that procedure A is the standard of care. And so I'm going to do insurance when paid for procedure A.
So we're going to do procedure B and figuring out that maze of data. I was wondering like how do you do it? Like I mean I look at from it from almost all. From a large big data set and go how do you make the connections or how much of that's kind of a little bit of an estimate.
It's tough. So you know we do our best and it becomes you know increasingly harder when you start looking at you know the world of you know I guess you know optometry and ophthalmology right so. You know primarily where you know our main customers at you know at this stage are primarily ophthalmologists but as we as we're learning you know you got to go further and further upstream so obviously you've got. The treating physician but you know where is that treating physician getting their patients from obviously in the majority it's the sea of you know call it 50,000 you know 50,000 plus optometrist across the US so you know it's it's.
Yeah how many people are holding patients too long exactly how many people are not diagnosing in the right amount of time and you've missed earlier treatment options and now you're doing more advanced treatment options. I yeah I mean I was one of that from a clinical perspective like I think sometimes we don't know what we don't know or we don't see what we don't see. And that dramatically affects the care of patients so what you know I look at that and go we've had this on other podcasts and other discussions and you and I had to discussion about this last time we talked about is you know how do we. We're always in this search for what evidence based medicine or real world evidence is but kind of get back to your disparate data thing is how do we actually know I mean how do we know who's prescribing what and how do you guys look at that from from an industry perspective and kind of make sense out of that.
Yeah I mean so and again I'm gonna start with the topic that I think you know I recall you and I have talked about one conversation or another is just the challenges with all the EHRs all the practice management systems and their inability to really talk to one another and efficient men are not only within you know a singular practice but in group practices and you know expanding beyond that so for us to be able to you know kind of a and clinicians I would imagine for for that matter. It's very difficult to track the patient journey over six months a year two years and truly understand what exactly is going on and then and then downstream from that getting our hands or access to you know kind of the efficacy brand or so the outcome you know because you know sometimes there are no sometimes they're not in the street fields they come out of systems differently so. You know obviously we've got objective data on medical claims prescriptions on and so forth but no you know in order for us to get our hands truly on you know the outcomes in the true picture of the patient journey it takes layers and layers of trying to put together you know claims from vendors where we know capture rate is you know suspect at best there's exclusivity agreements there's. You know that the ties between them are very difficult so yeah I mean I look at and think you know the my practice and the practice that I refer to.
Which are literally 30 minutes down the road from where I live we use the same EHR but we can't talk between each other and I look at my glaucoma surgeon I sent him for a procedure. A patient for a procedure in the glaucoma you know Zach calls me he's like hey Scotty goes well what's been the pressure readings what his visual fields look like what does OCT look like over the last year and I'm like well I've about 20 years worth of data is like could you send it all to me and I have to send it to him in a black and white facts which is insane right so you know how does that help him in a single analysis look at real what rate of change is and you know to say hey is this procedure better in somebody's faster. And somebody's faster rate of change or is this procedure a better in somebody's slow rate of change I think until we have integrated data where as you know that disparate system I think EHRs are disparate from each other as well as within the same EHR I think until we get that it's going to make real world. True evidence based medicine really difficult and without that we can't even think about getting to value based medicine it I look at glaucoma's and go if you could show that an ice tent or an idose or whatever.
You know cuts down the overall cost of glaucoma over a period of a decade how much would that be worth to the healthcare system well probably a lot but how do we figure that out. Yeah no exactly even on the other side where you've got you know potentially payers who have policies out there that you know require efficacy or you know kind of clinical data points at various points in time so if you've got you know optometrist. You know optometrist do and one thing specialist do and one thing you know how best you know effectively both parties manage their time any increased layers that you have of manual faxing you know putting that into a system downloading that in submitting it to a pa it just you know obviously I think the payers you know smart and notice but they're there they're real barriers to. Again you probably can answer this by the I can but you know making making informed decisions with kind of linear.
Time series data yeah I mean you're right I mean how does an insurance company know what progression rate is and in phenotype genotype A versus phenotype genotype B they just look at across the board and go no it's denied or no it's not covered or no it's because we don't have evidence but they're just as much insurance companies are just as much if not more blind and I say that in the night. I say that in the nicest possible way to what real data is is you know I always I use this analogy when I speak is you know if procedure A could save this healthcare company like I don't know let's pick one unit of healthcare could save them over the life of this patient tens of thousands of dollars yeah the procedure might cost 10 grand up front but it saves them 10 grand over the next decade. That seems like a pretty good deal versus let me just keep paying you know what's it what's a glaucoma drop it's a thousand dollars per eye per year is what the cost is to the system well if a procedure can save 10 years worth of drops wow that seems like a pretty good break even point for an insurance company but I think they're work they're they're making decisions totally. Totally or blindly at this point yeah exactly or if it's you know purposefully blind in the sense of I think I'm like a knee replacement you know there again I.
Yeah. There are more I think they're more incentivized to just try and kick that can down the road versus addressing the issue upfront because you know there's there's a chance that patient may not be with you know I did for the next 10 years there's a chance I can kick that cost over to that or whomever so obviously it comes at the detriment of the patient. And the same thing and so is blue cross and so is medicare so is everybody else right so exactly well so when you talk about kind of you know I've had this conversation about data silos right and I think that's kind of where we're getting at what do you see is the potential solution I mean I know when your job you use it there look at lots of data sets all day and how do we get around the data silo issue. It's a very difficult question without you know fully intricate knowledge of EHRs and practice management systems and the different configurations.
And then kind of the you know HIPAA rules and everything around how data comes out of these systems how it shared how it can be extracted so you know what I've learned over the years is there is no one size fits all solution for all of the issues that we have out there. What we do know is it's it's it's difficult each practice can extract data in different ways each person within that practice can have varying permissions to what data they can download what data they can use which makes it you know especially difficult on a manufacturer and some of the resources that we try and provide you know both the providers and patients because you know it takes a you know it takes human capital and human resources to kind of go in. Have the knowledge to be able to assist you know kind of what's needed you know how it's needed how we can submit it to certain payers you know completely in a way that we can you know do it at an arms link relationship to where you know completely we have to have you know kind of a value exchange on both sides so. So yeah I was looking at the one answer for it's tough no it's a no it is tough and I mean we've been talking about this for two years and Ray on and I have and I still not sure we have the answer yet I mean I think we everybody's got a little piece but I don't think it'd be really as the answer well so okay so let's say it was like because I was looking at industry you know and I'm biased because my wife is in in our industry and you know so I always think about if industry is our greatest advocates as clinical providers because they want to provide tools.
Help us provide better care what from your perspective Ryan what would industry like to see like if I'm going to go out and champion. The getting rid of the data silos and fixing disparate knowledge and you know database and stuff what would you say Scott this is what you need to go out and show from the mountaintop about what we need is industry. So you know I can't remember which episode it was but one of your podcasts you know I guess I'd mentioned something that resonated with me you know pretty quickly which was you know anything that we do obviously is all for you know we think patient first right well how can we help the patient in all regards but in order to do that you know any of the resources tools or strategies that we put forward you know you have to take into account both providers and the provider staff. So you know everybody's limited in time and resources so anything that we can do to me you know kind of you know provider you know constraints time provider efficiencies and that includes their staff so it's you know whether it's navigating whether it's navigating a commercial patient or a Medicare patient or a Medicare advantage patient like all of these things are.
Different so you know we spend a lot of time making sure you know our specific teams are experts in their domain so to you know to be able to understand quickly like you know what are the mechanisms with this patient what have we seen you know prior behavior from either this pair or plan as we know there's thousands and thousands of plans yeah I mean that's a that's a that's a whole. That's a beast on itself you know my my AI project that i've been working on for last couple years we're at that stage of trying to tie it all together and it's it's complex without a doubt but so if you could let's take that one step further if you could create. Okay so i'm going to look have you looking to the your crystal ball Ryan if you could design a perfect data exchange for lack of a better word ecosystem. What might that look like.
I you know I think it's again it's we've talked about a lot of the data you know few data set so far. But for for for me internally it's really about getting the most relevant data to all of the teams in a timely fashion that connects all the dots now you know some teams would use things differently than others but it's about connecting you know the claims data it's about connecting. You know some of the transparency and cover jewels that we know which essentially gives us insights into what is a you know particular physician group like what is their contract with some of these. Medicare advantage or commercial folks like do they have proper you know t codes or you know potential drug codes in there they even know what those t codes are.
Exactly can we get a hat up you know I guess directly answer your question is can we get a hat of predictable hiccups that are likely to happen. You know from basically the the clinician buying into a potential you know potential product being the best for the patient what can we do. Advanced of getting that into you know kind of the the wheel that churns in our health care system to make sure that listen like we did everything in our power so Scott and his staff don't have to go through the appeal process because what that's time and resources there's probably going to be incorrect or. In sufficient information that comes back and then you know basically creates a wheel of you know both confusion frustration it's frustration so.
Anything that we can identify ahead of time. To circumvent all of the known issues that we know happened from one that buttons clicked in the claim submitted or the physician decides this is the best treatment i'm going to go ahead and do it. What can we do to make it as seamless as possible all while understanding you and I are in this industry we've been in it for years and years and years and there are still times. We're all sitting on a call on something that we talked about a month ago with.
You know certain subject matters a market expert nice to left to go back to my notes and say okay what is this acronym what does this mean who does it impact and why does it happen I can't imagine. You know if you're a family member that's you know waiting to get on on you know something that your doctor prescribed all all. All will just understand why you know it's just confusion and and frustration you can't have this because well your insurance doesn't cover it well. You know I was looking at you know right you you know I had to talk about this is that you know I think to it industries biggest struggles not only do you have to have not only do all of your sales force.
Have to create you have to be experts in behavioral modification of the provider. To say hey here's what the real data says you're changing prescribing patterns and or surgical intervention patterns. You also have to as you said you know very eloquently is get rid of all the bottlenecks and obstacles that are causing problems like well if I prescribe this drug or if I. You know I want to do this procedure is it covered well how do we know well obviously if it's a cover if it's there's thousands of plans as you said.
And I think that until we can figure out a way that every provider. Every patient I think is patient to but even the sales force could have access to go hey this is what's covered with this plan for this patient that leaves some that that's what it's that transparency thing you and I've talked about is like how do we get transparency of what prescribing patterns are because some people are just there's some docs who are going nope I'm still prescribing a pile of carpet in a beta blocker and I'm like. Dude I mean there's like better drugs than that or you know why in the US are we the only people who prescribe drugs first and don't do procedures right and I think there's there's the evidence based medicine oh hey this is what this procedure really could do or what this drug can really do I think that that I'll answer my I'll answer your question I gave you is I think until we can kind of have a universal database it's going to be really difficult to have the transparency necessary to fix the disparate systems we have. Yeah, no exactly you know again I for some of our sales folks right or even you know your office staffs Scott if if you could walk into a consultation and have.
You know the information at your hands and maybe you do but I don't think it's widespread across offices in the way folks operate. But you know simple things like a you know green light yellow light like listen this this this patient has this patient has you know x diagnosis this patient has x insurance and based on you know historical prescribing and all that here's kind of your menu of unfortunately the four of seven options that that we can go with so. It's covered by insurance but exactly but then I look at it go yes but if we can then track the data Ryan maybe we can go back to insurance companies and go well hey I it's covered under I don't know i'm just picking one it's covered in our new night health care and cover blue cross but that you don't cover it but the success rate of this has been 75% of people are without drops for the next 10 years you're making a mistake because they don't as we discussed earlier the insurance company. They don't know the data either because all the data they get in fact they're less probably have less data than you do because as industry because they're only looking at CPT code.
Initial CPT code of what that procedure was and the diagnosis code they pay for the procedure they never track long term results they never know way to track it so they're making all of their decisions based on. Really incomplete data compared to what industry does or what practices do so maybe as we get to the spot we can track data better we can change who accepts what you know so. That that's crazy to think that i've been space medicine may actually be able to change what's covered. No I mean listen I agree and we've got you know over time at least in my time at cloud coast there's several initiatives that you know really try and get at that from from a clinical perspective obviously there's.
I was database and things of the like what that gives us the ability to. Educate and you know kind of form publications in the sense that exactly what you just kind of hit on which is that that ability to longitudinally track. Here's patients who got x here's how they perform at time points you know 369 12 months. To kind of really show to your point the evidence based you know approach of here's the outcomes of what happened over you know these time frames for over two years.
Of a 10 years right more than just the months and no there's always that risk of well patients are going to move from one practice to another practice and. You know you know you know i've been on the bandwagon for the last few years of until we have a universal system where patients own their own records and it goes with them. Tracking that longitudinal date is going to be challenging. But but I think that that's on its way I mean I think that's coming so Ryan what are you and so I mean maybe you can.
X maybe you can share your strategy but I don't want you to give away all of your corporate secrets so how do you make your with the data you have access to. How do you make your strategic decisions or are there places you're just like I know this is kind of a guesstimate. So. It's been you know it's always an evolving process you know but really it starts with again connecting the dots a little bit you know that that I kind of started with which is we've got to be able to take all of the.
All of the data sets that we have it on his bowls that we deem relevant so whether that be you know prescribing trends with particular physicians. Mixed with some of the market access related variables you know layering that on top of you know some of the. You know and I think I think I understand you but could you for the audience could you describe when you say act market access variables what do you what do you mean by that what do you consider. As those things I think that definition would be really helpful for the audience i mean i'll give you one example right we know in certain you know in certain populations.
You know a potential drug could be reimbursed ten thousand dollars at a facility in pala alto and sixty miles across the road that same joke can be reimbursed at. Four thousand dollars so you know it's just an unfortunate reality of. You know the system that you know we we seek to understand obviously combined with. All of the other elements that go into clinical you know the clinical decision but you know it really starts there so for us to be able to supplement.
You know the clinical buy-in and the clinical data with the physicians combined with. Some of the extra you know externality variables that you know impact adoption or not so so those are just a couple right the other pieces are understanding. The structure of you know the business that that the physician is operating in so is it a group is it a is it a private equity is it a private equity backed you know another. Another variable there when he gets it's not just a single practice now it's.
What are the decisions private equities making across thousands of practices or hundreds of. Exactly and what is that impact so we got to look you know upstream and downstream of that so as these consolidate. You know we always try and stay ahead of you know really understanding your customer at all levels so in in almost all cases right it's the provider starts with the provider you have the clinical buy-in piece. But you know it gets increasingly complex when you start to go into you know different layers and really understanding you know the barriers what when you have that clinical adoption so.
What whether we're you know talking to. C seats within some of these you know larger organizations what is their motive what are they care about so. We really try and attack that from all angles and truly understand you know for each of our team members when you're going into a conversation with someone. What is that conversation look like you know who's talked to these folks in the past what was discussed.
So so what's there what's their method of action and how does that different from maybe what other practices are doing that are being less or more successful right I mean now that's we're back to that behavioral modification of of not just the provider. But there's staff of how they're billing it or how they're accessing it or how they're figuring out what the deductible is or the out of pocket or. How they are they using the correct t codes are they you know all that kind of stuff I I think that you know I believe and you know roll it back into the AI part is that I believe that we're going to see an automation of most of that. To take clinical to take operational staff.
Out of the picture and I don't mean that in a negative way I just think that a lot of those frustrations of not doing it right. I do see a very in the very near future where there is a database of insurances that shows what everybody pays and what everybody submitted and what what I think AI will build to detect those challenges and fix those. So people within my staff or the staff of the practice I use for glaucoma surgery or cataract surgery. I think in the next three or four years we're going to see those challenges those obstacles disappear but there there are there's some definite challenges are getting around the what what EHRs will let us have access to.
Yeah certainly i agree with all that i guess the other piece I would you know kind of add on to that would be you know we've had you know a few initiatives internally without you know just closing too much where you know we've been able to. To work with customers on you know understanding their you know potentially their their own data so of course we've got. Third party claims and things that you know we can go out and buy. But what does that look like when we actually have a you know the collection of real world data from from our customers we know.
We've got some of that data and we've crunched it you know we had a few hypothesis. hypothesis or hypothesis about, you know, what we wanted to get out of it. And the interesting part is, you know, it morphed so quickly into wow, like he hears what we thought, you know, we would see and here's what we thought we wanted to help answer and, you know, turns out those those questions have, you know, they snowball right. And when we turn that around to some of our providers and say, you know, here's kind of what things look like, you know, sometimes the answer is look in the room is, who whose data is this?
Well, I really say, I'm sure, if you show that about my practice and I'm pretty anal about data, I'm sure I would go, what? Really? It's campy mind, you know, we're talking about mine. That's not what I do, but I was thinking about this way I write a prescription and patient comes back using something else and I'm like, well, wait, where did that go?
And I think about how many times, you know, those things change, I'm sure that if you as industry, you know, if you can provide that data transparently, I think that might be the change. I think that's one of those things that could change provider decision making, because I don't think we actually know we're so busy just. We're so busy just trying to see patients. I don't I think about how often do I sit there and just really dig into my, I might look dig into my financial data, but often do I dig into my clinical data.
I'm not sure I do it as much as I should. And some people I wonder if they do it at all. No, I would agree with all that based on, you know, some of the things that we see in the inconsistencies across, you know, here's what we think, you know, for a common example, here's what we think the defined agreed upon treatment protocol is, and the variations that we see chronologically with how, how procedures are performed, which procedure is it in what in what ICD or diagnosis group is it being performed in and why? And the lack of consistency or the lack of transparency into that even at the provider level.
I often wonder, you know, like, and I'll use dry eye for an example, I'll stay out of the glaucoma world for this one, but, you know, I often wonder how many times a procedure is done for a diagnosis that we use that diagnosis to get paid, even though that might not really be the diagnosis that had the last five or 10 years, we change that diagnosis to make it match. So, you know, does that happen? Of course it does, you know, and so would insurance companies look at and go, well, I don't really happy about that, but, you know, I know that happens, I'm sure it happens, but, you know, people learn how to play the game and maybe that's not a great system when we're having to figure out how to play the game to give people the care they really need. Yeah, yeah, again, I agree and, you know, bringing transparency and helping, you know, certain industries, glaucoma, or whatever it may be, given them transparency into, you know, some of the data trends within their own practice to me can be extremely powerful, like if we go into, you know, high, you know, a high volume cataract shop to in five, six thousand a year, you know, it's almost guaranteed that they know exactly where the funnel is exactly how many patients they've got turning through exactly what.
You know, the percent of conversion to premium I well, you asked some of the same questions and different, you know, sub therapeutic areas within ophthalmology. No idea what it is. It's trick it's. Yeah, the crickets, yeah, I mean, you could say the same thing from Thomartry about how many multifocal contacts are used or how much, you know, how many premium progressive lenses are you using and what's your sales sell through rate on patient a versus patient B it's not just surgical it's everything it's all of.
Procedural type stuff or retail for that matter so I have a question for you will kind of we try to keep these around 30 minutes Ryan so. Um, fascinating stuff different than anything we've heard from any of our other guests and that's why I so appreciate your time if you could. What do you see okay now here's another big crystal ball question I was trying to ask toward the end you know if you look at the next five years of innovation. Even if we just stay in the glauco space in the glauco space or in the premium I well space.
What do you see as tools that would be really useful. You talked about transparency I totally agree with that what tools you see as both useful and probably inevitable as coming down the path. So I guess my one my head goes first with that question it's a little bit you know I think we've touched on this a little bit Scott in the past which is the ability to upstream diagnose and get better information earlier in the process whether it be specific to you know a couple of the sub therapeutic areas that we're focused on but I think you know this comment probably was either cross most therapeutic areas which is. You know diagnosis typically happens to wait the referral happens probably later than it should.
And some of these wearable technologies the ability to 3d you know see see what's going on within the eye earlier upstream and the access to these technologies. So you know a broad scale of a way in the 50,000 plus optometrist that residing the US or even primary care right you know even at the recall you saying that refraction could be in a mall someday you know what I get it already is I mean it is now I mean that's that's a big big political debate debate right now in our profession but you know you can do a refraction with the heads up display you can do it in mall you can you know and I think in the near future we'll see like perimeter right I mean you guys. Have now one of the parametry companies that you can do heads up display perimetry instead of having a big device I think we're only going to see more I didn't even we didn't get into that heads up stuff you know or 3d virtual reality and I mean yeah Ryan I look at that go we might have data. We might have data that we didn't even we haven't even conceptualized I think when you could put an IOP sensor inside the eye.
How does that and you know you have AI crunch in the data 24 seven you know especially when it crunches as well here's pulse rate here's respiration here's your VO 2 max you know here's your heart rate here's your blood pressure that you're getting from your watch your ring your phone. Wow I think we might have insights we didn't even imagine. Yeah I mean obviously the idea of it all would be you know a lot of the interventions and a lot of the therapeutics that are out there are great they you know they manage symptoms but you know to the extent that we can catch things before irreversible damage is done is obviously the holy grail until you know we have cares for you know anything and all things that are possible. You know come you know coming down the pipeline but until you know patients are caught earlier and understand these things prior to getting to a specialist where you know you're already at stage 3 or whatever it may be is obviously you know all things that we continue to think about you know internally and I think AI is going to be just you know monumental in that shift towards properly diagnosing earlier and getting it you know getting patients to the proper physicians you know earlier on the path.
So for all of the audience I think the key take home I got from what Ryan just shared with us is that you know we all need to continue to work diligently and industriously to try to solve some of these challenges of where do we get our data is it transparent is it connected and how do we how do we connect all the tools to provide earlier access earlier diagnosis earlier treatment so maybe we can get a better treatment. We can prevent some of these like glaucoma some of these diseases that are visually threatening over lifetime so. Ryan I just want to say thank you for your time I so appreciate you I I love having our conversations because every time I do I'm like I have a list of about 15 things here I'm like oh I never really thought about that data disconnect I got to fix that you know so I appreciate all all of your help. Thanks for having me on Dr Morris you know it's a great discussion look forward to catching up soon.
You can always catch up with this real talk or any of our other real talks as well as our innovator series and many of our articles on AI in iCare.com you can also send any questions comments concerns or things you'd like to see in the podcast or articles to me at my email let's Scott SEO T at AI in iCare.ai. Thank you for your time today. You've been listening to real talk an AI in iCare your weekly podcast to keep you informed about AI technologies revolutionizing iCare.